Lijie Tan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article
Neoadjuvant chemoradiotherapy (CRT) held its own on safety outcomes in a head-to-head trial against neoadjuvant chemotherapy alone for locally advanced esophageal squamous cell carcinoma (SCC), an interim analysis of a randomized study from China found.
In the multicenter trial of more than 250 patients going on to minimally invasive surgery, the two approaches yielded similar rates of perioperative morbidity and mortality, as well as similar survival at 1 year, but significant histopathologic advantages emerged for the group receiving neoadjuvant CRT, reported Lijie Tan, MD, of Fudan University in Shanghai, and colleagues.
While more and more evidence has suggested the survival benefit from neoadjuvant therapy followed by surgery for locally advanced esophageal cancer, only three trials have directly compared neoadjuvant CRT and chemotherapy in this setting, the group wrote in ....

Li Jie , Marcog Patti , Fernandoam Herbella , Ian Ingram , Fudan University , University Of North Carolina , Lijie Tan , Escola Paulista De Medicina , North Carolina , Chapel Hill , Medpage Today , Deputy Managing Editor , Neoplastic Disease , Spinal Cord Compression , Squamous Cell Carcinoma , லி ஜிே , ஈயந் இஂக்ரம் , பல்கலைக்கழகம் ஆஃப் வடக்கு கரோலினா , எஸ்கோலா போஉலிஸ்த்ா டி மருத்துவ , வடக்கு கரோலினா , தேவாலயம் மலை , துணை நிர்வகித்தல் ஆசிரியர் , முதுகெலும்பு தண்டு சுருக்க ,